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Abstract
A heart attack kills off many cells in the heart. Parts of the heart become thin and fail to contract properly following the replacement of
lost cells by scar tissue. However, the notion that the same adult cardiomyocytes beat throughout the lifespan of the organ and organ-
ism, without the need for a minimum turnover, gives way to a fascinating investigations. Since the late 1800s, scientists and cardiolo-
gists wanted to demonstrate that the cardiomyocytes cannot be generated after the perinatal period in human beings. This curiosity has
been passed down in subsequent years and has motivated more and more accurate studies in an attempt to exclude the presence of
renewed cardiomyocytes in the tissue bordering the ischaemic area, and then to confirm the dogma of the heart as terminally differen-
tiated organ. Conversely, peri-lesional mitosis of cardiomyocytes were discovered initially by light microscopy and subsequently con-
firmed by more sophisticated technologies. Controversial evidence of mechanisms underlying myocardial regeneration has shown that
adult cardiomyocytes are renewed through a slow turnover, even in the absence of damage. This turnover is ensured by the activation
of rare clusters of progenitor cells interspersed among the cardiac cells functionally mature. Cardiac progenitor cells continuously inter-
act with each other, with the cells circulating in the vessels of the coronary microcirculation and myocardial cells in auto-/paracrine man-
ner. Much remains to be understood; however, the limited functional recovery in human beings after myocardial injury clearly demon-
strates weak regenerative potential of cardiomyocytes and encourages the development of new approaches to stimulate this process.
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Introduction
The adult human heart has been viewed as a static terminally dif-
ferentiated organ, formed of oriented mature cardiomyocytes that
allow for the conduction of electrical signals and the synchronous
contractile function aimed at maintaining the physiological sys-
temic perfusion. Adult human myocardium has been considered a
tissue capable of increasing its mass by hypertrophy of existing
myocytes in response to increased after- and/or pre-load. Indeed,
historical evidence highlighted that, in physiological or pathologi-
cal conditions, a post-natal mammalian cardiomyocyte could not
re-enter the cell cycle and replace itself. However, no clear evi-
dence in favour of the above possibility was provided prompting
the international scientific community to reveal the hidden truth in
definitive way. Since the late 1800s, the question of regeneration
of cardiac muscle fibres has often been discussed. Goldenberg [1]
reviewed the previous reports and concluded that longitudinal
splitting of cardiomyocytes could occur, yet the increase of cardiac
tissue was largely by hypertrophy of muscle fibres. Conversely,
other investigators demonstrated that the increase of the heart
mass was mainly due to hypertrophy rather than hyperplasia of
cardiomyocytes, on the basis of the lack of evidence of myocardial
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mitotic figures [2–5]. In the early 1920s, counts and measure-
ments of muscle fibres made by Collier [6] and Karsner et al. [7]
confirmed that myocardial hypertrophy and hyperplasia are
occurred. Thereafter, Macmahon [8] indicated that the principal
difficulty was failure to demonstrate mitotic figures in adult car-
diomyocyte nuclei, but not in myocardium of infants and children.
Thus opinions on cardiomyocyte turnover in adult heart was
divided for many years, but in the late 1960s and early 1970s the
evaluation of DNA synthesis in cardiomyocyte nuclei was shown
to be negligible, strengthening the notion that cardiomyocytes can
increase in volume but not in number [9, 10].
The steps forward of the molecular cardiology and the develop-
ment of advanced microscopy techniques have modified the scale of
analysis and allowed conceivable that the early cardiomyocyte
response to homeostatic and pathophysiological environments is a
dynamic consequence of alterations in the effector pathways, which
regulate myocyte growth and proliferation [11–14]. Intercellular sig-
nals are generated from resident cells functionally mature or imma-
ture, and tend to maintain a homeostatic code in order to preserve
the myocardial architecture. The dissection of the mechanisms is still
in progress and this is changing dramatically our understanding of
cardiac biology by witnessing the principles dictating initial cardiac
genesis during development so as to exclude any artefact.
Adult cardiomyocyte turnover
At birth the number of cardiomyocytes in the heart of mammals is
largely determined. The hyperplastic growth occurring during
embryonic life is quickly replaced by a hypertrophic process soon
after birth. Studies based on the method of incorporation of thymi-
dine showed that DNA synthesis accompanied by cytokinesis in
mice decreases from 70% at E8 to 45% at E11 and almost disap-
pears 1–2 days after birth [15]. In the second phase, starting just
after the birth, karyokinesis occurs in the absence of cytokinesis
thus determines an increasing percentage of binucleated cardiomy-
ocytes from 2.5% at day 2, to 80% at day 14 [16]. These two
distinct phases in the heart development are reflected in the expres-
sion levels of regulators of cell cycle such as cyclin-dependent
kinases (Cdks) and their inhibitors. The expression patterns of cell
cycle regulatory proteins are well reviewed by Pasumarthi K.B. &
Field L.J. [11]. In general, Cdks exert their positive effects in terms
of promoting mitosis of cardiac cells during the embryonic life
while they are down-regulated in the adult heart. Therefore, the
replicative capacity of the heart suffers a sharp slowdown after
birth and starting from this certainty, several scientists have won-
dered if the adult heart was still able to retain a regenerative capac-
ity in adult life. Recently, two independent studies have addressed
the issue following a similar approach but in two different species
[11, 17]. Although it was known that many invertebrates such as
the zebrafish can regenerate the heart after amputation up to 20%
[18]. Jopling et al. first established that the contribution of exist-
ing cardiomyocytes to regenerate tissue is of paramount impor-
tance. Using a CRE/lox approach they demonstrated that after par-
tial amputation of the ventricle, survived cardiomyocytes adjacent
to the damaged region express regulators of cell-cycle progres-
sion, such as plk1 and mps1, de-differentiate detaching from one
another. They lose their sarcomeric structure and re-enter the cell
cycle [19]. A more recent paper by Porrello et al. showed that sim-
ilar events occur in 1-day-old mouse when the ventricular apex is
resected. The region of resection is progressively interested by a
robust inflammatory response followed by the formation of blood
clot that is subsequently replaced by new functional heart, which
derives mainly from the pre-existing cardiomyocytes. At 21 days
the majority of the new formed cardiomyocytes were positive for
the mitotic index, phosphohistone H3 and the aurora B kinase. The
mouse heart loses its regenerative potential within the first week
of postnatal life [17]. While demonstrating the absolute impor-
tance of the existing cardiomyocytes in regenerating new cardiac
tissue, none of the above-cited papers can exclude the contribu-
tion of resident progenitor/stem cells.
Cardiac tissue generation: contribution
of resident interstitial cells
The adult myocardium is a well-organized tissue composed by dif-
ferent resident cell types forming a morpho-functional unit [20]:
cardiomyocytes, endothelial cells, smooth muscle cells and a vari-
ety of interstitial cells including cardiac resident stem/progenitor
cells (Fig. 1). Among the interstitial cells, cardiac fibroblasts, which
account for two-thirds of total myocardial cells, play important
physiological role in ensuring a spatial orientation, a structural
organization and mutual interplay of resident cardiac cells, which
work interdependently in order to promote an efficient global and
regional function of the heart [21]. The intrinsic characteristics of
tension-generating fibroblasts also have a continuous mechanical
interplay with their extrinsic environment [22]. Moreover, the car-
diac fibroblasts are the main myocardial source of collagen, which
composes the post-ischaemic infarct scar, and release several
humoral mediators involved in myocardial remodelling: proinflam-
matory cytokines, including tumour necrosis factor- (TNF-),
interleukin-1 (IL-1), and interleukin-6 (IL-6) [23, 24], growth fac-
tors involved in myocardial remodelling, such as platelet-derived
growth factor [25], high molecular weight fibroblast growth factor-
2 (FGF-2) [26], insulin-like growth factor-1 [27] and vascular
endothelial growth factor (VEGF) [28]. Cardiac fibroblasts are able
to interact with other interstitial cells resident into the myocardium,
such as mast cells (MCs) [29] and telocytes (TCs) [30].
Mast cells are multifunctional cells releasing different humoral
mediators, such as cytokines, and histamine, and they have been
identified in injured myocardium [31]. MCs have been suggested
also to play a role in adverse remodelling in human failing heart
[32]. Chymase, which is an enzyme stored in the cardiac MCs, is
insensitive to ACE inhibitors and promotes interstitial fibrosis by
affecting collagen metabolism via transforming growth factor-.
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Chronic chymase inhibition decreases the cardiac angiotensin II
levels, myocardial fibrosis and contractile failure [33]. Conversely,
Kwon et al. [34] recently showed that the intramyocardial injection
of MC granules prolonged survival of cardiomyocytes and pro-
moted angiogenesis in rodent infarcted hearts. However, the role
of cardiac MCs during remodelling, which are also CD117(),
remains controversial and some investigators even suggested
them as cardiac progenitor cells (CPCs) [35].
Telocytes have been recently described as a novel different
types of interstitial cell type in adult mammalian heart [36, 37].
They are characterized to shed exceptionally long cellular
processes – telopodes – which form an interstitial network, con-
necting different types of cell from myocardium, epicardium and
endocardium. TCs seem to be involved in a long distance intercel-
lular signalling, due to both membrane-to-membrane junction and
release of vesicles [30, 36]. TCs presumably contribute to neo-
angiogenesis via paracrine secretion of VEGF and microRNAs (e.g.
let-7e, 10a, 21, 27b, 100, 126–3p, 130a, 143, 155) [38].
Particularly important is the role of TCs in supporting the renewal
and survival of CPCs [30].
Cardiac progenitor cells reside in the heart as well as in other
solid organs, within niches that are composed of extracellular
matrix, stem/supporting cells and blood vessels [39, 40]. In the
last decade, several independent groups have tried to isolate pro-
genitor cells from adult heart tissue with a view to reuse them as
cell source for autologous cell transplantation in injured heart
[41–46]. With the heterogeneity of markers that have been chosen
to define cardiac progenitor populations, few scientists have both-
ered to study the role of these progenitors in the normal cardiac
physiology. So far it is not clear if these populations are related
and which is their origin. The in vitro condition that better recapit-
ulates the features of CPC niche is the three-dimensional culture
of CPCs as cardiospheres, in which the cell–cell and cell–matrix
interactions are conserved and the cell survival and functional
benefits are ensured [47, 48].
An indirect evidence that precursors may contribute to gener-
ate new cardiomyocytes in the area of the injury derives from
paper by Hsieh et al. [49]. They used an elegant ‘fate-mapping’
approach establishing a double transgenic mouse in which all the
cells positive for the cardiac specific promoter Mhy6 were consti-
tutively expressing the -galactosidase reporter gene (-gal).
The latest is replaced by the GFP when mice are pulsed with 4-OH
tamoxifen. Theoretically, all the cardiomyocytes that were -gal
become GFP after pulse. The findings consist in the fact that fol-
lowing the induction of the infarct in the transgenic mice, the num-
ber of GFP myocytes were significantly decreased with respect
to the -gal cells indicating the presence of new cardiomyocytes
deriving from the differentiation of progenitor cells. Although
Fig. 1 Cross-talk of resident cardiac cells. Schematic representation of resident cardiac cells potentially involved in myocardial regeneration and modali-
ties of intercellular cross-talk. Vs: vessels; CMs: cardiomyocytes; SCs: stem cells; F: fibroblast; TCs: telocytes; MCs: mast cells; P: paracrine action; A:
autocrine action; E: endocrine action.
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authors cannot exclude that some progenitors were labelled by the
4-OH-tamoxifen, the percentage of new cardiac cells in myocardial
infarction border areas that were not derived from the mitosis of
pre-existing cardiomyocytes, reached 34%. Thus cardiomyocytes
can be generated by activation of resident [50] or in part by migra-
tion of progenitor cells from distant organs [51]. Similar genetic
mapping approach to track cell fate in injured heart has been fol-
lowed by Loffredo et al. [52]. In this article, authors establish that
the dilution in GFP and complimentary increase in -gal  car-
diomyocytes in infarcted transgenic mice is associated with an
increase in the number of nkx2.5- and GATA4-positive progenitor
cells. Moreover, in the same set of experiments they were able to
asses that the delivery of exogenous bone marrow-derived c-kit
cells exert effects by releasing a paracrine factors able to stimulate
regenerative capacity of progenitors rather than proliferation of
pre-existing cardiomyocytes [52]. However, recent findings
showed that the function and potential plasticity of stem cells,
potentially activated or recruited after injury into the myocardium,
is impaired by aging [53] and severity of cardiac disease [54].
The consistency of cell turnover due to CPC differentiation was
analysed in mouse by the in vivo incorporation of the BrdU [40].
BrdU retaining myocyte was 19%, 15% and 10% in the apex, atria
and base–midregion, respectively [40].
In human beings who live much longer than rodents, it is rea-
sonable to expect a slow cell turnover that implies cardiomy-
ocytes replacement. Clear evidence that cell division occurs in
human heart is shown by Bergmann et al. [55]. During the Cold
War the concentration of 14C in the atmosphere had increased
sharply following an exponential fluctuation with a peak around
1963. By relating this information with the levels of 14C in 
the DNA of cardiomyocytes of individuals born before and after
the nuclear bomb tests, authors reached a conclusion that the
amount of 14C present in heart cells of individuals correspond to
atmospheric levels several years after the persons’ birth. It fol-
lows that the DNA of cardiomyocytes has been synthesized many
years after the birth thus implicating cell renewal. Using elaborate
mathematical models and excluding contamination of other cell
types by cell-sorting, authors came to the following conclusions:
at the age of 50, 55% of the cardiomyocytes remain from the time
birth and 45% have been generated later; cardiomyocytes are
renewed at a rate of ~1% per year at the age of 25, 0.45% at the
age of 75; the age of cardiomyocytes is on average 6 years
younger than the individual.
This article was recently criticized in numbers and methodol-
ogy by Kajstura J. et al. [56]. They use a different approach
based on the detection of the iododeoxyuridine, analogue of
thymidine, into the cardiac cells of patients undergoing infusion
of this radiosensitizer. The results were ‘dramatically’ different
with an average of myocytes renewal of about 22% per year sug-
gesting that the heart is capable to renew itself several times
during the course of life [56]. Moreover, the myocyte turnover
increases further with age reaching the 40% in a heart of female
of 100 years of age.
The above experimental evidence, obtained by the use of more
accurate technologies than optical microscopy, seemed to have
answered the question that tormented too long cardiovascular
pathologists. Over the next two decades, the significant lack of fur-
ther technological progress had mitigated the interest in the field
of regenerative cardiology maturing awareness that a deep under-
standing of the mechanisms should be guaranteed only by a
change of point of view of the biological phenomena.
Signalling of miocardiogenesis: a
developmental perspective
Unravelling how different signalling pathways dictate cardiac 
precursor specification and subsequent behaviour is critical for
predicting how damaged myocardium will self-renew (Fig. 1). To
date, studies on cardiogenesis offered new hypothesis to highlight
the mechanisms underlying the regeneration of adult myocardium.
Several signalling pathways integrate and cross-talk during car-
diogenesis and it is conceivable that multiple molecular inputs
regulate the balance in the earliest steps of cardiogenesis through
mesoderm specification and allocation.
TNF-related weak inducer of apoptosis (TWEAK), a member of
the TNF- family, regulates proliferation in multiple cell types and
its effects are mediated through the activation of fibroblast growth
factor-inducible molecule 14 (FN14) receptor [57]. TWEAK caused
a dose-dependent increase in DNA synthesis of cardiomyocytes
and down-regulates the cell cycle inhibitor p27KIP1.
TWEAK/FN14-mediated patterning involves the activation of ERK,
and PI3K, as well as inhibition of GSK-3 which in turn led to sta-
bilization and accumulation of total -catenin and accumulation of
dephosphorylated -catenin in the nucleus. However, TWEAK
does not affect proliferation of adult rat cardiomyocytes due to
progressive down-regulation of FN14 gene and protein expression
after birth. Therefore, a guided post-natal overexpression of FN14
receptor is able to induce an efficient cell cycle reentry in adult car-
diomyocytes on the basis of the presence of endogenous TWEAK
protein in these cells [14]. Terminal differentiation of organ
involves the retinoblastoma family of tumour-suppressor pocket
proteins and Cdks that modulate their function [58]. However, the
role of these proteins has been substantiated in cardiac cell cycle
control [59] and needs the activity of telomerase reverse tran-
scriptase (TERT). Continuous cell division erodes the telomeric
repeat because of incomplete replication of the distal 39 strand
during active replicative growth [60]. In adult human beings,
telomerase activity is found predominantly in germ cells, tumour
cells and stem cells but not somatic cells that ultimately senesce.
Failure to express TERT is the principal mechanism for low levels
of telomerase activity seen with replicative senescence.
Telomerase activity and TERT expression are lacking or are
markedly decreased in the adult heart, but not during cardiogene-
sis [61]. On the basis of this notion, Oh et al. [62] showed that the
replacement of ancestral telomerase activity in adult cardiomy-
ocytes delays cell cycle exit, induces hypertrophy and promotes
cardiac myocyte survival.
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Other investigations showed that Nodal/Activin/TGF-b, bone
morphogenetic proteins (BMPs) and FGFs drive cardiogenesis
[63] and suggested how their re-activation might improve the self-
regenerative capacity of the heart.
BMPs promote mesoderm formation from embryonic stem cells
through a Wnt/Activin/Nodal-dependent mechanism [64]. Thereafter,
Notch regulates CPC proliferation and fate through an interaction
with Wnt/b-catenin signalling [64]. Previous study showed that
cardiomyogenesis in the adult heart depends on the activation and
differentiation of cardiac stem cells [65]. In accordance with the tra-
ditional model of development of self-renewing organs, stem cells
give rise to progenitor precursor cells, which then proliferate and
eventually reach terminal differentiation and growth arrest. Newly
generated cardiomyocytes might proliferate and concurrently differ-
entiate, mimicking cellular hyperplasia and hypertrophy [66].
Activation of the Notch1 cascade is crucial for cell-to-cell interaction
during cardiovascular development and may influence differentia-
tion, proliferation and apoptotic events of CPC [67, 68]. Alteration of
Notch1 pathway hampers coronary vessel wall maturation during
myocardium growth and development [69] and even predisposes to
the onset of lethal cardiomyopathy [70]. Notch1 signalling is limited
by the abundance of Notch1, which is transcriptionally controlled by
Nrf2 (nuclear factor erythroid-derived 2-related factor 2), which is a
prosurvival transcription factor that plays a pivotal role in maintain-
ing cellular homeostasis following oxidative stress [71–73] and pro-
inflammatory state [74] in adult heart. Nrf2-mediated regulation of
Notch1 expression may be most critical in postnatal stages, rather
than during development, because Nrf2 disruption does not produce
altered phenotypes during early development stages. Nrf2 is abun-
dant in tissues containing stem cells, such as liver, kidney and gas-
trointestinal-tract. Wakabayashi et al. [75] showed original evidence
that Nrf2 facilitates tissue regeneration in the liver by regulating
Notch1 expression. Moreover, recent experimental evidence showed
that an increased expression of Nrf2 improves the effectiveness of
cell therapy delivered in infarcted rodent heart [76].
Wnt signalling has been shown to influence the development of
the heart. Recent data suggested canonical Wnts promote the
emergence and expansion of cardiac progenitors in the pregas-
trula embryo. Martin et al. showed that canonical Wnt signalling
up-regulates expression of the cardiac stem cell marker c-kit and
pluripotency genes Oct25 and Oct60 without a corresponding
inhibition of cardiogenic differentiation [77].
During cardiomyogenesis, Notch and TGF- signalling path-
ways are involved in endothelial-to-mesenchymal transition of
endothelial cells. Notch activation modulates TGF- signalling
pathways in a receptor-activated Smad-specific manner [78]. In
particular, Notch increases SMAD3 mRNA expression and cooper-
atively induces histone H4 acetylation in cooperation with TGF-.
Recently, Maioli et al. [79] showed that the transcription of the
cardiogenic gene Nkx-2.5 in embryonic stem cells is enhanced
through Smad4 binding to its own consensus Smad site. The
above signalling pathway driving cardiogenesis is modulated by
novel molecules, which maintains acetylation of histone H4 in
stem cells and adult cardiomyocytes, such as hyaluronan mixed
esters of butyric and retinoic acids [80].
Imaging of self-renewed myocardium
The phenomenon of myocardial self-regeneration needs more
detectable and quantifiable evidence in response to historical con-
troversies [81]. In the past, it was very difficult to determine the
sequence of the process of myocardial remodelling and/or repair
after an injury as well as the plausible interference of a therapy
during the healing’s phase without the use of histological analysis
and, therefore, the sacrifice of a large number of animals. In addi-
tion, the tools available were not advanced enough to promote
accurate morphological and functional study at regional and
molecular level. So, it was common opinion that the no detection
of a global cardiac effect, such as following a potential healing
treatment, reflects the absence of an adaptive response post-
injury (repair/regeneration), which was rather active regionally to
a different scale. To date, the technological progress in non-inva-
sive diagnosis allowed the development of more accurate tools for
the ongoing detection of new forming coronary vessels or
myocardium as well as for the real-time assessment at higher
magnification of contractile function and structure in vivo [82–84].
The process of myocardial remodelling is initiated with a number
of dynamic adverse effects in injured heart. Firstly, the non-con-
tracting tissue expands and becomes thinner. The extreme thin-
ning of the infarcted cardiac wall is easily detectable in both ani-
mal models and human beings. Secondly, the reactive growth of
the cardiac tissue causes an increased volume load, after which
compensatory mechanisms also lead to an increased pressure
load on the heart. The mechanical overload results in LV hypertro-
phy and then dilation with increasing of LV cavity volume.
Finally, the occurrence of myoarchitectural disarray in the ven-
tricular wall, i.e. the presence of abnormally organized cardiomy-
ocytes, characterizes the remodelled myocardium in cardiovascu-
lar disease, such as hypertrophic cardiomyopathy, hypertension
and myocardial infarction [85]. The cardiac muscle architecture
lies at the basis of the mechanical and electrical properties of the
heart, and dynamic alterations in fibre structure are known to be
of prime importance in healing and remodelling after myocardial
infarction. The amount of disarray present in the hearts after
myocardial infarction, in both the border areas and the scar tissue
formed by the infarction, is quantifiable by magnetic resonance
imaging (MRI). In fact, diffusion tensor imaging offers a non-
destructive tool for the study of myocardial fibre orientations 
[86, 87] as well as for the evaluation of structural tissue changes
caused by ischaemia [88].
Myocardial wall anatomy and function of normal/injured cardiac
regions are also accurately assessed by MRI using velocity encod-
ing, tagging or DENSE (displacement encoding with stimulated
echo) imaging [89–92]. The delayed enhancement-MRI of the
infarcted myocardial wall after injection of a gadolinium-based con-
trast agent has been demonstrated to correlate with infarct size [93].
Regional myocardial wall perfusion in infarcted heart is quanti-
fied by positron emission tomography (PET) after intravenous
injection of specific radiotracers, such as 13NH3 (ammonia) 
[91, 94], 11C-acetate [95] or (15)O-labelled water [96]. Recent
J. Cell. Mol. Med. Vol 16, No 2, 2012
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investigations also demonstrated that it is feasible to quantify
regional myocardial perfusion in ischaemic heart using gated sin-
gle photon emission computed tomography (SPECT) [97] or
hybrid SPECT/coronary computed tomography angiography tech-
nology [98]. The nuclear medicine has made possible an accurate
assessment of the myocardial viability through a monitoring of its
metabolism. Radionuclide modalities currently used in the assess-
ment of viability include (201)Tl SPECT, (99m)Tc-based SPECT
imaging and (18)F-fluorodexoyglucose ((18)F-FDG)-PET imaging.
The initial myocardial uptake early after systemic delivery of thal-
lium reflects the magnitude of the regional blood flow. However,
redistribution of 201Tl is related to the rate of 201Tl ‘washout’ from
the myocardium, dependent on the thallium concentration gradi-
ent between myocytes, blood pool and the integrity of the mem-
brane-based Na/K ATPase pump [99].
Despite 201Tl, 99mTc-based radiopharmaceuticals have a worse
relationship to flow and minimal redistributing properties, and the
mitochondrial uptake of these compounds requires an intact mito-
chondrial membrane and oxidative metabolism, thus the basis for
sensitive viability detection [100]. Recent study compared the
detection of viable myocardium by 18F-FDG, MRI and 99mTc-ses-
tamibi (MIBI) and demonstrated that a significantly higher number
of segments were identified as scar by MIBI than by either 18F-FDG
or CMR [101]. However, the greatest discrepancy between MIBI
and 18F-FDG and MRI was in detection of scar of the inferior and
lateral wall. Cardiac PET utilizing 18F-FDG is considered the most
sensitive modality for detecting scar and viable myocardium. To
date, 18F-FDG PET is considered the most sensitive means of
assessing viable myocardium and hence predicting LV functional
recovery post-coronary revascularization [102].
However, no single imaging modality can provide all the informa-
tion required to monitor the repair or regeneration of injured
myocardium; hence, there is a necessity for combining complemen-
tary imaging methodologies. Indeed, the combination of MRI and
PET modalities allows the acquisition of anatomical, physiological
and metabolic information from the same subject. Recent study
showed that multimodal imaging approach allowed an accurate and
regional assessment of the new myocardium regenerated after car-
diac transplantation of stem cells [103–106] or administration of
new drugs, which elicit self-repair of the myocardium, such as
hyaluronan mixed esters of butyric and retinoic acid [80]. These
studies showed that the myocardial structure, function and viability
of infarcted heart following regenerative treatment is equal to unin-
jured myocardium and the infarct scar size is significantly reduced.
Conclusions
Since ancient times, the heart’s ability to regenerate itself has
always intrigued the human curiosity. Hyginus has narrated the
myth of Prometheus, the Titan punished by the wrath of Zeus for
stealing the fire from the gods. The Prometheus’s heart grows
back during the night after being eaten by eagle on the day. The
mythology seems to have foreseen that the human heart could
not beat for the whole life with the same cardiomyocytes. The
heart is an organ exposed to constant and variable mechanical
forces and so it is potentially exposed to wear. The heart, similar
to all adult tissues, has a plasticity that provides a partial renewal,
yet it is weak, slow and limited. The plasticity of the heart
depends both on rare cardiac progenitors resident into orderly
architecture of the myocardium as well as on continuous cross-
talk with other cells that shape the adult myocardium (cardiomy-
ocytes, endothelial cells, fibroblasts), and it is also due to own
ability of the myocardium to recruit and activate circulating
inflammatory and progenitor cells. Some pathways of intercellu-
lar communication have been revealed ensuring the development
of new pharmacological modulators. The future perspective will
be to identify the complete code by which heart cells communi-
cate with each other to promote a slow and continuous regener-
ation of the cells worn by mechanical forces and vascular insults.
This new frontier of research in the cardiovascular field will lead
to the affirmation of the pro-regenerative drugs for the treatment
of cardiac dysfunction.
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